177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

Who May Qualify: - Giving a written willing to sign a consent form - Histopathologically confirmed high or very high risk prostate cancer - Completion of radical locoregional treatment - Completion of locoregional treatment within 3 months before inclusion to the study - You should be able to carry out daily activities with 0 level of ability (ECOG 0) to 2 - Age over 18 years - Within 28 days before entering the study, there were no signs of cancer dissemination documented in radiological tests - Castrate testosterone level (testosteron \< 50 ng/dL lub 1,7 nmol/L) - Patients with adequate function of main organs: - bone marrow: - neutrophils \> 1500x10\^9/L; - thrombocytes \> 100,000x10\^9/L; - hemoglobin \> 9 g/dL - liver: - bilirubin \< 2xULN (upper limit of normal) in patients with Gilbert's syndrome \< 5xULN; - aminotransferase \< 3xULN - kidneys: - eGFR \> 50 ml/min - albumin \>2.5 mg/ml - For men of reproductive age: the need to use double barrier contraception Who Should NOT Join This Trial: - The presence of distant metastases confirmed by radiological examination - Absence of approval to use effective contraception method - Absence of Patient's consent to participate in the Study - Urinary tract obstruction or/and hydronephrosis. - Concurrent anticancer treatment. Always talk to your doctor about whether this trial is right for you.